Last reviewed · How we verify
Hormone receptor-positive, HER2-negative breast cancer
Approved treatments
Pipeline
- PF-06804103 + Palbociclib +Letrozole · Pfizer Inc. — Phase 1
Clinical guidelines
- FDA label — 2L
Everolimus tablets are indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane, after failure of treatment with letrozole or anastrozole. - FDA label — 2L
Everolimus tablets are indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease. - FDA label — 2L
Everolimus tablets are indicated for the treatment of adult patients with progressive, well-differentiated, non-functional NET of gastrointestinal (GI) or lung origin with unresectable, locally advanced or metastatic disease. - FDA label — 2L
Everolimus tablets are indicated for the treatment of adult patients with advanced RCC after failure of treatment with sunitinib or sorafenib. - FDA label — any
Everolimus tablets are indicated for the treatment of adult patients with renal angiomyolipoma and TSC, not requiring immediate surgery.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Hormone receptor-positive, HER2-negative breast cancer patent landscape — cliff calendar, originator estates, attackable patents
- Hormone receptor-positive, HER2-negative breast cancer treatment landscape brief
- Hormone receptor-positive, HER2-negative breast cancer treatment updates RSS
Frequently asked questions about Hormone receptor-positive, HER2-negative breast cancer
What new drugs are in development for Hormone receptor-positive, HER2-negative breast cancer?
1 pipeline drugs tracked. Top candidates: PF-06804103 + Palbociclib +Letrozole.
What are the treatment guidelines for Hormone receptor-positive, HER2-negative breast cancer?
FDA label publishes guidelines for Hormone receptor-positive, HER2-negative breast cancer. 5 guideline references tracked.
Related
- Treatment landscape: Hormone receptor-positive, HER2-negative breast cancer patent cliff · Hormone receptor-positive, HER2-negative breast cancer CI report
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing